SCHEMBL16166267

SCHEMBL16166267

CCOC(=O)c1cnn(Cc2ccc(Cl)cn2)c1N

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.65
LMNA P02545 2/20 0.65
ALDH1A1 P00352 5/20 0.64
HTT P42858 1/20 0.53
RAB9A P51151 5/20 0.50
KDM4E B2RXH2 2/20 0.50
HPGD P15428 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
KMT2A Q03164 3/20 0.49
TSHR P16473 4/20 0.49
TP53 P04637 1/20 0.48
MEN1 O00255 1/20 0.46
MAPT P10636 2/20 0.45
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16166249 0.85 NPC1 (0.83) NPC1LMNAALDH1A1HTTRAB9A
SCHEMBL16175844 0.83 TSHR (0.56) NPC1LMNAALDH1A1RAB9AKDM4E
SCHEMBL16166354 0.81 TSHR (0.53) NPC1LMNAALDH1A1RAB9AKDM4E
SCHEMBL16166275 0.81 CYP19A1 (0.50) ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1
SCHEMBL16166191 0.81 ALDH1A1 (0.76) NPC1LMNAALDH1A1HTTRAB9A
SCHEMBL4832108 0.79 NPC1 (0.81) NPC1LMNAALDH1A1HTTRAB9A
SCHEMBL10513542 0.79 NPC1 (0.70) NPC1LMNAALDH1A1HTTRAB9A
SCHEMBL19780049 0.78 NPC1 (0.67) NPC1LMNAALDH1A1HTTRAB9A
SCHEMBL173434 0.77 NPC1 (0.68) NPC1LMNAALDH1A1HTTRAB9A
SCHEMBL370942 0.76 LMNA (0.80) NPC1LMNAALDH1A1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014167528-A1 SPIROPYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS NOVARTIS AG (CH) 2014-10-16 WO disclosed
WO-2014167528-A1 SPIROPYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS NOVARTIS AG (CH) 2014-10-16 WO disclosed